Targeting DNA repair in cancer: current state and novel approaches

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• DNA damage response, repair, and genomic instability are crucial in cancer initiation and progression.
• Next-generation sequencing reveals mutations and epigenetic silencing in cancer genes involved in these processes.
• DNA repair's role in therapeutic response drives clinical exploitation of research findings.

Purpose of the Study:

• To review recent advancements in DNA damage response (DDR) and novel DNA repair inhibition agents.
• To explore the synergistic potential of combining DDR inhibitors with immunotherapy.
• To discuss the role of epigenetic drugs in modulating DNA repair pathways and sensitizing cancer cells.

Main Methods:

• Literature review of recent preclinical and clinical studies.
• Analysis of findings from next-generation sequencing in cancer cohorts.
• Discussion of drug development targeting DNA repair components.

Main Results:

• Numerous small molecules targeting DNA repair are in clinical trials, inspired by PARP1/2 inhibitor success.
• Emerging strategies involve combining DNA repair inhibitors with immunotherapy.
• Epigenetic drugs show potential in altering DNA repair activity and enhancing therapy sensitivity.

Conclusions:

• Targeting DNA damage response and repair pathways offers promising therapeutic strategies for cancer.
• Combination therapies involving DNA repair inhibitors, immunotherapy, and epigenetic drugs are areas of active investigation.
• Further research is needed to fully exploit these mechanisms for improved cancer treatment outcomes.